Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies

<table>Change in wart count compared with baseline (left axis, circle, mean, ITT, last observation carried forward) versus local skin reaction (LSR) sum score (right axis, square, mean, observed) over time for imiquimod 3.75% during the evaluation phase. Maximum LSR sum score = 18. Shaded box indicates treatment period of up to 8 weeks. <svg height="11.175" id="M22" style="vertical-align:-0.0pt" version="1.1" viewbox="0 0 10.9375 11.175" width="10.9375" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
<g transform="matrix(.017,-0,0,-.017,.062,11.113)"><path d="M619 482q0 -69 -40.5 -119t-96 -72.5t-118.5 -26.5h-44l-70 20l-31 -151q-14 -67 0.5 -83t89.5 -22l-5 -28h-287l8 28q65 7 81.5 22t29.5 83l79 398q12 56 0.5 70.5t-78.5 20.5l7 28h255q108 0 164 -43t56 -125zM524 478q0 141 -146 141q-25 0 -47 -8q-16 -6 -20.5 -13.5
t-10.5 -39.5l-43 -241q37 -13 83 -13q67 0 125.5 45t58.5 129z" id="x1D443"></path></g>
</svg> values were calculated using analysis of covariance, controlling for baseline wart count, and analysis site.*indicates statistically significant for active versus placebo, and <sup>†</sup>for imiquimod 3.75% versus 2.5%, using Hochberg's modified Bonferroni procedure.</table>

Infectious Diseases in Obstetrics and Gynecology

fig4

Figure 4

Figure 4: Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies 